Safety Alert: Epimax Ointment Products The MHRA has issued a safety alert regarding Epimax Ointment and Epimax Paraffin-Free Ointment due to reports of ocular surface toxicity and ocular chemical injury. Key Points Both Epimax Ointment and Epimax Paraffin-Free Ointment can cause serious eye damage if applied to the face Cases of ocular surface toxicity and […]
MHRA Alert – June 2024 Medicine Recalls and Safety Letters
Important Safety Update from the MHRA The Medicines and Healthcare products Regulatory Agency (MHRA) has published a summary of letters and notifications issued to healthcare professionals during June 2024. This update covers recent medicine recalls and safety communications affecting clinical practice. What You Need to Know The MHRA regularly issues safety alerts and recalls to […]
MHRA Alert – Topiramate: New Pregnancy Prevention Programme Requirements
Important Safety Update: Topiramate (Topamax) The MHRA has introduced new safety measures for topiramate following a comprehensive review of its use in pregnancy. Topiramate is now contraindicated in pregnancy and in women of childbearing potential unless strict conditions are met. Key Points Topiramate carries a significant risk of birth defects and developmental disorders when used […]
MHRA Alert – Warfarin and Tramadol: Critical Drug Interaction Risk
Important Safety Alert The MHRA has issued a safety alert regarding a significant drug interaction between warfarin and tramadol. This combination can cause harmful interactions that elevate the International Normalised Ratio (INR) and result in severe bruising, bleeding, and in some cases, fatal outcomes. Key Points Warfarin and tramadol together increase the risk of serious […]
MHRA Alert – May 2024 Medicine Recalls and Safety Updates
MHRA Safety Update: May 2024 Recalls and Letters The MHRA has published a summary of letters and safety notifications issued to healthcare professionals during May 2024. This update covers recent medicines and medical device alerts that may affect your clinical practice and patient care. What You Need to Know The MHRA regularly communicates important safety […]
MHRA Alert – Topical Steroids: New Labelling and Withdrawal Risk Reminder
MHRA Safety Update: Topical Steroids The MHRA has issued an important reminder about topical steroid safety, with new labelling coming to products in the coming months. While these medications are safe and effective for managing inflammatory skin conditions, prolonged use—especially at high potency—carries significant risks that all clinicians and responders should be aware of. Key […]
MHRA Alert – April 2024 Medicine Recalls and Safety Updates
April 2024 MHRA Safety Communications The MHRA has published a comprehensive summary of letters and safety notifications issued to healthcare professionals during April 2024. This update covers recent medicine recalls and device safety information relevant to clinical practice across all care settings. Key Points This monthly summary consolidates important safety communications that may affect your […]
MHRA Alert – Finasteride: Psychiatric and Persistent Sexual Side Effects
Key Safety Update on Finasteride The MHRA has issued a reminder about important side effects associated with finasteride, a commonly prescribed medication for male pattern baldness and benign prostatic hyperplasia. A new patient alert card is being introduced to raise awareness among men taking this drug. What You Need to Know Finasteride carries a documented […]
MHRA Alert – Montelukast and Neuropsychiatric Reactions in All Ages
Important Safety Reminder The MHRA has issued a reminder about the risk of neuropsychiatric reactions associated with montelukast use. This alert applies to all patient groups, including children and adolescents, and reinforces previous safety communications on this issue. Key Safety Points Neuropsychiatric reactions have been reported in patients taking montelukast Reported effects include sleep disorders, […]
MHRA Alert – March 2024 Medicine Recalls and Safety Updates
March 2024 MHRA Safety Communications The MHRA has published a summary of letters and notifications issued to healthcare professionals during March 2024 concerning medicines and medical devices. This update consolidates important safety information relevant to clinical practice across primary and secondary care. Key Points Multiple safety communications were issued in March 2024 affecting various medicines […]